Heart Diseases

There are many different types of heart diseases. The most common type is coronary artery disease, or the narrowing of the coronary arteries. This important vessel carries blood to the heart.

Programs + Services

Clinical Nutrition

The Division of Clinical Nutrition at Tufts Medical Center provides inpatient and outpatient nutritional services.
More information about programs and services

Finest cardiovascular care

Our CardioVascular Center provides highly personalized care for a wide range of cardiovascular conditions. Learn how we formulate a treatment for your specific needs.
More information about programs and services

Doctors + Care Team

Amanda Vest, MBBS, MPH

Amanda Vest, MBBS, MPH

Accepting New Patients

Title(s): Medical Director, Cardiac Transplantation Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Cardiology, heart failure, cardiomyopathies (including cardiac amyloidosis, sarcoidosis) heart transplantation, mechanical circulatory support, pregnancy and heart disease (including peripartum cardiomyopathy)

View Full Profile for Amanda Vest, MBBS, MPH

Charles D.  Resor, MD, MSc

Charles D. Resor, MD, MSc

Accepting New Patients

Title(s): Cardiologist; Assistant Director, Cardiac Catheterization Lab; Associate Director, Interventional Cardiology Fellowship; Assistant Professor of Medicine, Tufts University School of Medicine
Department(s): CardioVascular Center, Interventional Cardiology and Structural Heart Disease
Appt. Phone: 617-636-2273
Fax #: 617-636-5913

Interventional cardiology, structural heart disease and intervention, aortic stenosis, TAVR trans aortic valve replacement, MitraClip, mechanical circulatory support

View Full Profile for Charles D. Resor, MD, MSc

Frederick  Y. Chen, MD, PhD

Frederick Y. Chen, MD, PhD

Accepting New Patients

Title(s): Chief, Cardiac Surgery; Professor of Surgery, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices, hypertrophic cardiomyopathy (HCM)

View Full Profile for Frederick Y. Chen, MD, PhD

Joel B. Mason, MD

Joel B. Mason, MD

Accepting New Patients

Title(s): Gastroenterologist; Professor, Tufts University Schools of Medicine and Friedman School of Nutritional Science and Policy; Senior Scientist and Director, Vitamins and Carcinogenesis Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Department(s): Medicine, Clinical Nutrition, Gastroenterology
Appt. Phone: 617-636-5883
Fax #: 617-636-1480

Malabsorption and unintentional weight loss, Inflammatory bowel disease, nutritional aspects of gastrointestinal disease, home nutritional therapy, enteral and parenteral nutrition

View Full Profile for Joel B. Mason, MD

Nicole M Orr, MD, FACC

Nicole M Orr, MD, FACC

Accepting New Patients

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone:
Fax #:

Geriatric cardiology, echocardiography

View Full Profile for Nicole M Orr, MD, FACC

Sameer K.  Chinoy, MD

Sameer K. Chinoy, MD

Accepting New Patients

LGBTQ Health

Title(s): Primary Care Physician; Assistant Professor, Tufts University School of Medicine
Department(s): Internal Medicine and Adult Primary Care
Appt. Phone: 617-636-5400
Fax #: 617-636-1384

Adult Primary Care

View Full Profile for Sameer K. Chinoy, MD

Research + Clinical Trials

Global cVAD Registry

The Global cVAD Registry collects data retrospectively from hospital medical records for patients, who received one or multiple Impella devices during routine care. This registry is an observational, multicenter, retrospective records review. The purpose of this registry is to capture data that reflects 'real world' use of Impella devices in clinical practice and provide insight into patient characteristics, overall health, patterns of care, quality of care and performance during the hospital stay. 
More information about research and clinical trials

HeartMate PHP™ Coronary Interventions in High-Risk Patients Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 60 sites in the US. Control device will be the Abiomed Impella® Recover® LP 2.5 Percutaneous Cardiac Support System.

Additionally, the study will include a nonrandomized roll-in phase at each site. Each site must first enroll and treat up to 3 patients in the nonrandomized roll-in phase before entering the randomized phase.

Assess the safety and efficacy of the HeartMate PHP in supporting patients with severe symptomatic coronary artery disease with diminished but stable cardiovascular function, who are undergoing elective or urgent high risk percutaneous coronary interventions (PCI) but are not candidates for coronary artery bypass graft (CABG) surgery.

Proposed Indications The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent,

hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.  Nonrandomized Roll-In Phase: Up to 180 patients undergoing PCI per the Inclusion/Exclusion criteria; up to 3 roll-in patients per site.

Randomized Phase: Up to 425 patients undergoing PCI per the Inclusion/Exclusion criteria.

Data will be collected at baseline, during the PCI procedure, postprocedure, discharge, and 90 days post device removal.

All patients will have a follow-up visit at 90 days post-device removal.

More information about research and clinical trials

Transcatheter Aortic Valve Replacement to Unload the Left ventricle in patients with Advanced heart failure: a randomized trial  (TAVR UNLOAD)

The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.

Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis

More information about research and clinical trials

Evaluation of Time to detection of Hyperglycemia And of Nursing Ease of use (ETHANE) 

The OptiScanner® 5000 Glucose Monitoring System from OptiScan Biomedical Corporation is an automated, bedside glucose monitoring system designed to quantitatively measure the concentration of venous blood glucose. The objective of this study is to evaluate the performance of the OptiScanner 5000 Glucose Monitoring System, a continuous, automated glucose monitor for the Surgical ICU. The OptiScanner 5000 Glucose Monitoring System (OptiScanner) will decrease time spent obtaining glucose values, improve efficiency and increase nursing satisfaction in the Surgical ICU, specifically in administering care to patients who require frequent bedside glucose monitoring. The OptiScanner will allow for earlier detection of hyperglycemia follow cardiac surgeries which require cardiopulmonary bypass by automating glucose measurement collection and displaying trending data. 
More information about research and clinical trials

A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More information about research and clinical trials